- Home
- JKHY vs QGEN Comparison
JKHY vs QGEN Comparison
Compare JKHY & QGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JKHY
- QGEN
- Stock Information
- Founded
- JKHY 1976
- QGEN 1986
- Country
- JKHY United States
- QGEN Netherlands
- Employees
- JKHY N/A
- QGEN N/A
- Industry
- JKHY Retail: Computer Software & Peripheral Equipment
- QGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- JKHY Technology
- QGEN Health Care
- Exchange
- JKHY Nasdaq
- QGEN Nasdaq
- Market Cap
- JKHY 12.6B
- QGEN 10.1B
- IPO Year
- JKHY N/A
- QGEN 1996
- Fundamental
- Price
- JKHY $149.46
- QGEN $47.79
- Analyst Decision
- JKHY Hold
- QGEN Buy
- Analyst Count
- JKHY 8
- QGEN 8
- Target Price
- JKHY $180.88
- QGEN $51.01
- AVG Volume (30 Days)
- JKHY 1.2M
- QGEN 1.1M
- Earning Date
- JKHY 11-04-2025
- QGEN 11-05-2025
- Dividend Yield
- JKHY 1.54%
- QGEN 3.23%
- EPS Growth
- JKHY 19.31
- QGEN 405.09
- EPS
- JKHY 6.24
- QGEN 1.69
- Revenue
- JKHY $2,375,288,000.00
- QGEN $2,040,067,000.00
- Revenue This Year
- JKHY $6.98
- QGEN $7.37
- Revenue Next Year
- JKHY $6.41
- QGEN $5.70
- P/E Ratio
- JKHY $24.13
- QGEN $27.64
- Revenue Growth
- JKHY 7.21
- QGEN 5.15
- 52 Week Low
- JKHY $144.12
- QGEN $37.63
- 52 Week High
- JKHY $196.00
- QGEN $51.88
- Technical
- Relative Strength Index (RSI)
- JKHY 36.79
- QGEN 56.92
- Support Level
- JKHY $144.13
- QGEN $43.74
- Resistance Level
- JKHY $151.81
- QGEN $47.16
- Average True Range (ATR)
- JKHY 2.64
- QGEN 0.62
- MACD
- JKHY 0.15
- QGEN 0.36
- Stochastic Oscillator
- JKHY 39.35
- QGEN 96.49
About JKHY Jack Henry & Associates Inc.
Jack Henry is a leading provider of core processing and complementary services, such as electronic funds transfer, payment processing, and loan processing for US banks and credit unions, with a focus on small and midsize banks. Jack Henry serves almost 1,000 banks and over 700 credit unions.
About QGEN Qiagen N.V.
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2024 sales), followed by EMEA (33%), and the Asia-Pacific (15%).